Vimarsana
Biggest News Aggregation in the World

High Content Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from High Content Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In High Content Analysis Today - Breaking & Trending Today

ViQi, Inc. announces Pascal Bamford, Ph.D. and Timothy Spicer, Ph.D. have joined the board of directors and scientific advisory board, respectively - Vimarsana News

ViQi, Inc. announces Pascal Bamford, Ph.D. and Timothy Spicer, Ph.D. have joined the board of directors and scientific advisory board, respectively

Santa Barbara, CA (PRWEB) September 15, 2022 -- Pascal Bamford, Ph.D., is senior vice president of research and development and laboratory operations at

Source: prweb.com
Cell Analysis Global Market to Reach $38.02 Billion by 2029 - Vimarsana News

Cell Analysis Global Market to Reach $38.02 Billion by 2029

/PRNewswire/ -- The "Cell Analysis Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. According to analysis, the...

Global High Content Screening Market (2022 to 2027) - - Vimarsana News

Global High Content Screening Market (2022 to 2027) -

Dublin, April 08, 2022 (GLOBE NEWSWIRE) -- The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...

SLAS Discovery's June issue on synthetic biology available now - Vimarsana News

SLAS Discovery's June issue on synthetic biology available now

The June edition of SLAS Discovery features the cover article, 'A Perspective on Synthetic Biology in Drug Discovery and Development -- Current Impact and Future Opportunities' by Florian David, Ph.D. (Chalmers University of Technology, Gothenburg, Sweden), Andrew M. Davis, Ph.D. (AstraZeneca, Cambridge, England, UK). Michael Gossing, Ph.D., Martin A. Hayes, Ph.D., and Elvira Romero, Ph.D., and Louis H. Scott, Ph.D. (AstraZeneca, Gothenburg, Sweden), and Mark J. Wigglesworth, Ph.D. (AstraZeneca, London, England, UK).